Targeting receptor tyrosine kinase MET in cancer: Small molecule inhibitors and clinical progress

Journal of Medicinal Chemistry

Volumn 57, Issue 11, 2014, Pages 4427-4453

  Cui, J Jean ^a  

^a TP Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOXORUBICIN; EMD 1204831; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; INDOLE DERIVATIVE; JNJ 38877605; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NVP BUV 972; PACLITAXEL; PANITUMUMAB; PF 04217903; PF 04254644; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; QUINOLINE DERIVATIVE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SGX 523; STAT PROTEIN; STAUROSPORINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AUTOPHOSPHORYLATION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG TARGETING; GENE DOSAGE; GENE MUTATION; HUMAN; HYDROGEN BOND; IC 50; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84902449207     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401427c     Document Type: Review

References (184)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298, 1912-1934 (Pubitemid 35425239)
2. Lemmon, M. A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases Cell 2010, 141, 1117-1134
3. Gschwind, A.; Fischer, O. M.; Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy Nat. Rev. Cancer 2004, 4, 361-370 (Pubitemid 38579482)
4. Trusolino, L.; Bertotti, A.; Comoglio, P. M. MET signalling: principles and functions in development, organ regeneration and cancer Nat. Rev. Mol. Cell Biol. 2010, 11, 834-848
5. Gherardi, E.; Birchmeier, W.; Birchmeier, C.; Vande Woude, G. Targeting MET in cancer: rationale and progress Nat. Rev. Cancer 2012, 12, 89-103
6. Ma, P. C.; Tretiakova, M. S.; MacKinnon, A. C.; Ramnath, N.; Johnson, C.; Dietrich, S.; Seiwert, T.; Christensen, J. G.; Jagadeeswaran, R.; Krausz, T.; Vokes, E. E.; Husain, A. N.; Salgia, R. Expression and mutational analysis of MET in human solid cancers Genes, Chromosomes Cancer 2008, 47, 1025-1037
7. Maulik, G.; Shrikhande, A.; Kijima, T.; Ma, P. C.; Morrison, P. T.; Salgia, R. Role of the hepatocyte growth factor receptor, MET, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev. 2002, 13, 41-59 (Pubitemid 34436961)
8. Wilson, T. R.; Fridlyand, J.; Yan, Y.; Penuel, E.; Burton, L.; Chan, E.; Peng, J.; Lin, E.; Wang, Y.; Sosman, J.; Ribas, A.; Li, J.; Moffat, J.; Sutherlin, D. P.; Koeppen, H.; Merchant, M.; Neve, R.; Settleman, J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 2012, 487, 505-509
9. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C. M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Jänne, P. A. MET amplication leads to gefitinib resistance in lung cancer by activating ERBB signaling Science 2007, 316, 1039-1043 (Pubitemid 46799492)
10. Turke, A. B.; Zejnullahu, K.; Wu, Y. L.; Song, Y.; Dias-Santagata, D.; Lifshits, E.; Toschi, L.; Rogers, A.; Mok, T.; Sequist, L.; Lindeman, N. I.; Murphy, C.; Akhavanfard, S.; Yeap, B. Y.; Xiao, Y.; Capelletti, M.; Iafrate, A. J.; Lee, C.; Christensen, J. G.; Engelman, J. A.; Jänne, P. A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 2010, 17, 77-88
11. Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z. R.; Du, J.; Davis, A.; Mongare, M. M.; Gould, J.; Frederick, D. T.; Cooper, Z. A.; Chapman, P. B.; Solit, D. B.; Ribas, A.; Lo, R. S.; Flaherty, K. T.; Ogino, S.; Wargo, J. A.; Golub, T. R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 2012, 487, 500-504
12. Cooper, C. S.; Park, M.; Blair, D. G; Tainsky, M. A.; Huebner, K.; Croce, C. M.; Vande Woude, G. F. Molecular cloning of a new transforming gene from a chemically transformed human cell line Nature 1984, 311, 29-33 (Pubitemid 14065275)
13. Dean, M.; Park, M.; Le Beau, M. M.; Robins, T. S.; Diaz, M. O.; Rowley, J. D.; Blair, D. G.; Vande Woude, G. F. The human MET oncogene is related to the tyrosine kinase oncogenes Nature 1985, 318, 385-388 (Pubitemid 16198499)
14. Park, M.; Dean, M.; Kaul, K.; Braun, M. J.; Gonda, M. A.; Vande Woude, G. F. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 6379-6383 (Pubitemid 18002806)
15. Giordano, S.; Ponzetto, C.; Di Renzo, M. F.; Cooper, C. S.; Comoglio, P. M. Tyrosine kinase receptor indistinguishable from the MET protein Nature 1989, 339, 155-156 (Pubitemid 19122275)
16. Gherardi, E.; Youles, M. E.; Miguel, R. N.; Blundell, T. L.; Iamele, L.; Gough, J.; Bandyopadhyay, A.; Hartmann, G.; Butler, P. J. G. Functional map and domain structure of MET, the product of the MET protooncogene and receptor for hepatocyte growth factor/scatter factor Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12039-12044 (Pubitemid 37271511)
17. Ponzetto, C.; Bardelli, A.; Zhen, Z.; Maina, F.; dalla Zonca, P.; Giordano, S.; Graziani, A.; Panayotou, G.; Comoglio, P. M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family Cell 1994, 77, 261-271 (Pubitemid 24138623)
18. Bottaro, D. P.; Rubin, J. S.; Faletto, D. L.; Chan, A. M.; Kmiecik, T. E.; Vande Woude, G. F.; Aaronson, S. A. Identification of the hepatocyte growth factor receptor as the MET proto-oncogene product Science 1991, 251, 802-804 (Pubitemid 21926175)
19. Shimomura, T.; Denda, K.; Kitamura, A.; Kawaguchi, T.; Kito, M.; Kondo, J.; Kagaya, S.; Qin, L.; Takata, H.; Miyazawa, K.; Kitamura, N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor J. Biol. Chem. 1997, 272, 6370-6376 (Pubitemid 27118113)
20. Kawaguchi, T.; Qin, L.; Shimomura, T.; Kondo, J.; Matsumoto, K.; Denda, K.; Kitamura, N. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor J. Biol. Chem. 1997, 272, 27558-27564 (Pubitemid 27473546)
21. Holmes, O.; Pillozzi, S.; Deakin, J. A.; Carafoli, F.; Kemp, L.; Butler, P. J.; Lyon, M.; Gherardi, E. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains J. Mol. Biol. 2007, 367, 395-408 (Pubitemid 46295423)
22. Basilico, C.; Arnesano, A.; Galluzzo, M.; Comoglio, P. M.; Michieli, P. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of MET J. Biol. Chem. 2008, 283, 21267-21277
23. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. MET, metastasis, motility and more Nat. Rev. Mol. Cell Biol. 2003, 4, 915-925 (Pubitemid 37493640)
24. Eder, J. P.; Vande Woude, G. F.; Boerner, S. A.; LoRusso, P. M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin. Cancer Res. 2009, 15, 2207-2214
25. Weidner, K. M.; Di Cesare, S.; Sachs, M.; Brinkmann, V.; Behrens, J.; Birchmeier, W. Interaction between Gab1 and the MET receptor tyrosine kinase is responsible for epithelial morphogenesis Nature 1996, 384, 173-176 (Pubitemid 26386473)
26. Mosesson, Y.; Mills, G. B.; Yarden, Y. Derailed endocytosis: an emerging feature of cancer. Nat. Rev Cancer 2008, 8, 835-850
27. Joffre, C.; Barrow, R.; Ménard, L.; Calleja, V.; Hart, I. R.; Kermorgant, S. A direct role for MET endocytosis in tumorigenesis Nat. Cell Biol. 2011, 13, 827-837
28. Hammond, D. E.; Urbé, S.; Vande Woude, G. F.; Clague, M. J. Down-regulation of MET, the receptor for hepatocyte growth factor Oncogene 2001, 20, 2761-2770 (Pubitemid 32549833)
29. Foveau, B.; Ancot, F.; Leroy, C.; Petrelli, A.; Reiss, K.; Vingtdeux, V.; Giordano, S.; Fafeur, V.; Tulasne, D. Down-regulation of the MET receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis Mol. Biol. Cell 2009, 20, 2495-2507
30. Michieli, P.; Mazzone, M.; Basilico, C.; Cavassa, S.; Sottile, A.; Naldini, L.; Comoglio, P. M. Targeting the tumor and its microenvironment by a dual-function decoy MET receptor Cancer Cell 2004, 6, 61-73 (Pubitemid 38903162)
31. Di Renzo, M. F.; Narsimhan, R. P.; Olivero, M.; Bretti, S.; Giordano, S.; Medico, E.; Gaglia, P.; Zara, P.; Comoglio, P. M. Expression of the MET/HGF receptor in normal and neoplastic human tissues Oncogene 1991, 6, 1997-2003 (Pubitemid 21924039)
32. Tajima, H.; Higuchi, O.; Mizuno, K.; Nakamura, T. Tissue distribution of hepatocyte growth factor receptor and its exclusive down-regulation in a regenerating organ after injury J. Biochem. 1992, 111, 401-406
33. Comoglio, P. M.; Trusolino, L. Invasive growth: from development to metastasis J. Clin. Invest. 2002, 109, 857-862 (Pubitemid 34275105)
34. Schmidt, C.; Bladt, F.; Goedecke, S.; Brinkmann, V.; Zschiesche, W.; Sharpe, M.; Gherardi, E.; Birchmeier, C. Scatter factor/hepatocyte growth factor is essential for liver development Nature 1995, 373, 699-702
35. Uehara, Y.; Minowa, O.; Mori, C.; Shiota, K.; Kuno, J.; Noda, T.; Kitamura, N. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor Nature 1995, 373, 702-705
36. Bladt, F.; Riethmacher, D.; Isenmann, S.; Aguzzi, A.; Birchmeier, C. Essential role for the MET receptor in the migration of myogenic precursor cells into the limb bud Nature 1995, 373, 768-771
37. Maina, F.; Hilton, M. C.; Ponzetto, C.; Davies, A. M.; Klein, R. MET receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons Genes Dev. 1997, 11, 3341-3350 (Pubitemid 28023958)
38. Sachs, M.; Brohmann, H.; Zechner, D.; Müller, T.; Hülsken, J.; Walther, I.; Schaeper, U.; Birchmeier, C.; Birchmeier, W. Essential role of Gab1 for signaling by the MET receptor in vivo J. Cell Biol. 2000, 150, 1375-1384
39. Huh, C. G.; Factor, V. M.; Sánchez, A.; Uchida, K.; Conner, E. A.; Thorgeirsson, S. S. Hepatocyte growth factor/MET signaling pathway is required for efficient liver regeneration and repair Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 4477-4482 (Pubitemid 38437436)
40. Michalopoulos, G. K.; DeFrances, M. C. Liver regeneration Science 1997, 276, 60-66
41. Liu, Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action Am. J. Physiol.: Renal Physiol. 2004, 287, F7-F16
42. Chmielowiec, J.; Ruge, F.; Price, P.; Harding, K. G.; Jiang, W. G. MET is essential for wound healing in the skin J. Cell Biol. 2007, 177, 151-162 (Pubitemid 46588409)
43. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-674
44. Cepero, V.; Sierra, J. R.; Giordano, S. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis Curr. Pharm. Des. 2010, 16, 1396-1409
45. Comoglio, P. M.; Giordano, S.; Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat. Rev. Drug Discovery 2008, 7, 504-516 (Pubitemid 351767118)
46. Boccaccio, C.; Comoglio, P. M. Invasive growth: a MET-driven genetic programme for cancer and stem cells Nat. Rev. Cancer 2006, 6, 637-645 (Pubitemid 44140861)
47. Hepatocyte Growth Factor/Scatter Factor (HGF/SF), MET and Cancer References. http://www.vai.org/MET/Index.aspx.
48. Migliore, C.; Giordano, S. Molecular cancer therapy: Can our expectation be MET? Eur. J. Cancer 2008, 44, 641-651
49. Ma, P. C.; Jagadeeswaran, R.; Jagadeesh, S.; Tretiakova, M. S.; Nallasura, V.; Fox, E. A.; Hansen, M.; Schaefer, E.; Naoki, K.; Lader, A.; Richards, W.; Sugarbaker, D.; Husain, A. N.; Christensen, J. G.; Salgia, R. Functional expression and mutations of MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer Cancer Res. 2005, 65, 1479-1488 (Pubitemid 40270177)
50. van Leenders, G. J.; Sookhlall, R.; Teubel, W. J.; de Ridder, C. M.; Reneman, S.; Sacchetti, A.; Vissers, K. J.; van Weerden, W.; Jenster, G. Activation of MET induces a stem-like phenotype in human prostate cancer PLoS One 2011, 6, e26753
51. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P. M. Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene Cancer Cell 2003, 3, 347-361 (Pubitemid 38340304)
52. Casaletto, J. B.; McClatchey, A. I. Spatial regulation of receptor tyrosine kinases in development and cancer Nat. Rev. Cancer 2012, 12, 387-400
53. Patanè, S.; Avnet, S.; Coltella, N.; Costa, B.; Sponza, S.; Oliverom, M.; Vigna, E.; Naldini, L.; Baldini, N.; Ferracini, R.; Corso, S.; Giordano, S.; Comoglio, P. M.; Di Renzo, M. F. MET overexpression turns human primary osteoblasts into osteosarcomas Cancer Res. 2006, 66, 4750-4757
54. Houldsworth, J.; Cordon-Cardo, C.; Ladanyi, M.; Kelsen, D. P.; Chaganti, R. S. Gene amplification in gastric and esophageal adenocarcinomas Cancer Res. 1990, 50, 6417-6422 (Pubitemid 20323708)
55. Umeki, K.; Shiota, G.; Kawasaki, H. Clinical significance of MET oncogene alterations in human colorectal cancer Oncology 1999, 56, 314-321 (Pubitemid 29240357)
56. Beau-Faller, M.; Ruppert, A. M.; Voegeli, A. C.; Neuville, A.; Meyer, N.; Guerin, E.; Legrain, M.; Mennecier, B.; Wihlm, J. M.; Massard, G.; Quoix, E.; Oudet, P.; Gaub, M. P. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort J. Thorac. Oncol. 2008, 3, 331-339 (Pubitemid 351489471)
57. Tong, C. Y.; Hui, A. B.; Yin, X. L.; Pang, J. C.; Zhu, X. L.; Poon, W. S.; Ng, H. K. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization J. Neurosurg. 2004, 100, 187-193 (Pubitemid 38141346)
58. Beroukhim, R.; Getz, G.; Nghiemphu, L.; Barretina, J.; Hsueh, T.; Linhart, D.; Vivanco, I.; Lee, J. C.; Huang, J. H.; Alexander, S.; Du, J.; Kau, T.; Thomas, R. K.; Shah, K.; Soto, H.; Perner, S.; Prensner, J.; Debiasi, R. M.; Demichelis, F.; Hatton, C.; Rubin, M. A.; Garraway, L. A.; Nelson, S. F.; Liau, L.; Mischel, P. S.; Cloughesy, T. F.; Meyerson, M.; Golub, T. A.; Lander, E. S.; Mellinghoff, I. K.; Sellers, W. R. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 20007-20012
59. Lennerz, J. K.; Kwak, E. L.; Ackerman, A.; Michael, M.; Fox, S. B.; Bergethon, K.; Lauwers, G. Y.; Christensen, J. G.; Wilner, K. D.; Haber, D. A.; Salgia, R.; Bang, Y. J.; Clark, J. W.; Solomon, B. J.; Iafrate, A. J. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib J. Clin. Oncol. 2011, 29, 4803-4810
60. Zeng, Z. S.; Weiser, M. R.; Kuntz, E.; Chen, C. T.; Khan, S. A.; Forslund, A.; Nash, G. M.; Gimbel, M.; Yamaguchi, Y.; Culliford, A. T., 4th; D'Alessio, M.; Barany, F.; Paty, P. B. MET gene amplification is associated with advanced stage colorectal cancer and liver metastases Cancer Lett. 2008, 265, 258-269
61. Smolen, G. A.; Sordella, R.; Muir, B.; Mohapatra, G.; Barmettler, A.; Archibald, H.; Kim, W. J.; Okimoto, R. A.; Bell, D. W.; Sgroi, D. C.; Christensen, J. G.; Settleman, J.; Haber, D. A. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 2316-2321 (Pubitemid 43271667)
62. Ma, P. C.; Tretiakova, M. S.; MacKinnon, A. C.; Ramnath, N.; Johnson, C.; Dietrich, S.; Seiwert, T.; Christensen, J. G.; Jagadeeswaran, R.; Krausz, T.; Vokes, E. E.; Husain, A. N.; Salgia, R. Expression and mutational analysis of MET in human solid cancers Genes, Chromosomes Cancer 2008, 47, 1025-1037
63. Ghiso, E.; Giordano, S. Targeting MET: why, where and how? Curr. Opin. Pharmacol. 2013, 13, 511-518
64. Schmidt, L.; Duh, F. M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S. W.; Zhuang, Z.; Lubensky, I.; Dean, M.; AllikMETs, R.; Chidambaram, A.; Bergerheim, U. R.; Feltis, J. T.; Casadevall, C.; Zamarron, A.; Bernues, M.; Richard, S.; Lips, C. J.; Walther, M. M.; Tsui, L. C.; Geil, L.; Orcutt, M. L.; Stackhouse, T.; Lipan, J.; Slife, L.; Brauch, H.; Decker, J.; Niehans, G.; Hughson, M. D.; Moch, H.; Storkel, S.; Lerman, M. I.; Linehan, W. M.; Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat. Genet. 1997, 16, 68-73 (Pubitemid 27198158)
65. Giordano, S.; Maffe, A.; Williams, T. A.; Artigiani, S.; Gual, P.; Bardelli, A.; Basilico, C.; Michieli, P.; Comoglio, P. M. Different point mutations in the MET oncogene elicit distinct biological properties FASEB J. 2000, 14, 399-406 (Pubitemid 30086077)
66. Graveel, C. R.; London, C. A.; Vande Woude, G. F. A mouse model of activating MET mutations Cell Cycle 2005, 4, 518-520 (Pubitemid 41359769)
67. Ghadjar, P.; Blank-Liss, W.; Simcock, M.; Hegyi, I.; Beer, K. T.; Moch, H.; Aebersold, D. M.; Zimmer, Y. MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers Clin. Exp. Metastasis 2009, 26, 809-815
68. Michieli, P.; Basilico, C.; Pennacchietti, S.; Maffè, A.; Tamagnone, L.; Giordano, S.; Bardelli, A.; Comoglio, P. M. Mutant MET-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists Oncogene 1999, 18, 5221-5231 (Pubitemid 29460658)
69. Gumustekin, M.; Kargi, A.; Bulut, G.; Gozukizil, A.; Ulukus, C.; Oztop, I.; Atabey, N. HGF/MET overexpressions, but not MET mutation, correlates with progression of non-small cell lung cancer Pathol. Oncol. Res. 2012, 18, 209-218
70. Peschard, P.; Park, M. From Tpr-MET to MET tumorigenesis and tubes Oncogene 2007, 26, 1276-1285
71. Otsuka, T.; Takayama, H.; Sharp, R.; Celli, G.; LaRochelle, W. J.; Bottaro, D. P.; Ellmore, N.; Vieira, W.; Owens, J. W.; Anver, M.; Merlino, G. MET autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype Cancer Res. 1998, 58, 5157-5167 (Pubitemid 28521177)
72. Xie, Q.; Bradley, R.; Kang, L.; Koeman, J.; Ascierto, M. L.; Worschech, A.; De Giorgi, V.; Wang, E.; Kefene, L.; Su, Y.; Essenburg, C.; Kaufman, D. W.; DeKoning, T.; Enter, M. A.; O'Rourke, T. J.; Marincola, F. M.; Vande Woude, G. F. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 570-575
73. Kentsis, A.; Reed, C.; Rice, K. L.; Sanda, T.; Rodig, S. J.; Tholouli, E.; Christie, A.; Valk, P. J.; Delwel, R.; Ngo, V.; Kutok, J. L.; Dahlberg, S. E.; Moreau, L. A.; Byers, R. J.; Christensen, J. G.; Vande Woude, G.; Licht, J. D.; Kung, A. L.; Staudt, L. M.; Look, A. T. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia Nat. Med. 2012, 18, 1118-1122
74. Tokunou, M.; Niki, T.; Eguchi, K.; Iba, S.; Tsuda, H.; Yamada, T.; Matsuno, Y.; Kondo, H.; Saitoh, Y.; Imamura, H.; Hirohashi, S. MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma Am. J. Pathol. 2001, 158, 1451-1463 (Pubitemid 32281309)
75. Vaupel, P. The role of hypoxia-induced factors in tumor progression Oncologist 2004, 9, 10-17 (Pubitemid 39658341)
76. Hayashi, M.; Sakata, M.; Takeda, T.; Tahara, M.; Yamamoto, T.; Okamoto, Y.; Minekawa, R.; Isobe, A.; Ohmichi, M.; Tasaka, K.; Murata, Y. Up-regulation of MET protooncogene product expression through hypoxia-inducible factor-1 alpha is involved in trophoblast invasion under low-oxygen tension Endocrinology 2005, 146, 4682-4689 (Pubitemid 41446605)
77. Bhardwaj, V.; Cascone, T.; Cortez, M. A.; Amini, A.; Evans, J.; Komaki, R. U.; Heymach, J. V.; Welsh, J. W. Modulation of MET signaling and cellular sensitivity to radiation: potential implications for therapy Cancer 2013, 119, 1768-1775
78. De Bacco, F.; Luraghi, P.; Medico, E.; Reato, G.; Girolami, F.; Perera, T.; Gabriele, P.; Comoglio, P. M.; Boccaccio, C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer J. Natl. Cancer Inst. 2011, 20, 645-661
79. Aebersold, D. M.; Kollar, A.; Beer, K. T.; Laissue, J.; Greiner, R. H.; Djonov, V. Involvement of the hepatocyte growth factor/scatter factor receptor MET and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation Int. J. Cancer 2001, 96, 41-54 (Pubitemid 32147684)
80. Kim, Y. J.; Go, H.; Wu, H. G.; Jeon, Y. K.; Park, S. W.; Lee, S. H. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy Head Neck 2011, 33, 1458-1466
81. Skibinski, G.; Skibinska, A.; James, K. Hepatocyte growth factor (HGF) protects MET-expressing Burkitt's lymphoma cell lines from apoptotic death induced by DNA damaging agents Eur. J. Cancer 2001, 37, 1562-1569 (Pubitemid 32744689)
82. Bowers, D. C.; Fan, S.; Walter, K. A.; Abounader, R.; Williams, J. A.; Rosen, E. M.; Laterra, J. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways Cancer Res. 2000, 60, 4277-4283 (Pubitemid 30636617)
83. Mitamura, T.; Watari, H.; Wang, L.; Kanno, H.; Hassan, M. K.; Miyazaki, M.; Katoh, Y.; Kimura, T.; Tanino, M.; Nishihara, H.; Tanaka, S.; Sakuragi, N. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET Oncogenesis 2013, 2, e40
84. Tang, M. K.; Zhou, H. Y.; Yam, J. W.; Wong, A. S. MET overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2 Neoplasia 2010, 12, 128-138
85. Avan, A.; Quint, K.; Nicolini, F.; Funel, N.; Frampton, A. E.; Maftouh, M.; Pelliccioni, S.; Schuurhuis, G. J.; Peters, G. J.; Giovannetti, E. Enhancement of the antiproliferative activity of gemcitabine by modulation of MET pathway in pancreatic cancer Curr. Pharm. Des. 2013, 19, 940-950
86. Lackner, M. R.; Wilson, T. R.; Settleman, J. Mechanisms of acquired resistance to targeted cancer therapies Future Oncol. 2012, 8, 999-1014
87. Crespan, E.; Zucca, E.; Maga, G. Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models Curr. Med. Chem. 2011, 18, 2836-2847
88. Trusolino, L.; Bertotti, A. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation Cancer Discovery 2012, 2, 876-880
89. Logue, J. S.; Morrison, D. K. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy Genes Dev. 2012, 26, 641-650
90. Sequist, L. V.; Waltman, A. W.; Dias-Santagata, D.; Digumarthy, S.; Turke, A. B.; Fidias, P.; Bergethon, K.; Shaw, A. T.; Gettinger, S.; Cosper, A. K.; Akhavanfard, S.; Heist, R. S.; Temel, J.; Christensen, J. G.; Wain, J. C.; Lynch, T. J.; Vernovsky, K.; Mark, E. J.; Lanuti, M.; Iafrate, A. J.; Mino-Kenudson, M.; Engelman, J. A. Genotyping and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci. Transl. Med. 2011, 3, 75ra26
91. Yu, H. A.; Arcila, M. E.; Rekhtman, N.; Sima, C. S.; Zakowski, M. F.; Pao, W.; Kris, M. G.; Miller, V. A.; Ladanyi, M.; Riely, G. J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin. Cancer Res. 2013, 19, 2240-2247
92. Turke, A. B.; Zejnullahu, K.; Wu, Y. L.; Song, Y.; Dias-Santagata, D.; Lifshits, E.; Toschi, L.; Rogers, A.; Mok, T.; Sequist, L.; Lindeman, N. I.; Murphy, C.; Akhavanfard, S.; Yeap, B. Y.; Xiao, Y.; Capelletti, M.; Iafrate, A. J.; Lee, C.; Christensen, J. G.; Engelman, J. A.; Jänne, P. A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 2010, 17, 77-88
93. Yano, S.; Wang, W.; Li, Q.; Matsumoto, K.; Sakuramam, H.; Nakamura, T.; Ogino, H.; Kakiuchi, S.; Hanibuchi, M.; Nishioka, Y.; Uehara, H.; Mitsudomi, T.; Yatabe, Y.; Nakamura, T.; Sone, S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res. 2008, 68, 9479-9487
94. Bardelli, A.; Corso, S.; Bertotti, A.; Hobor, S.; Valtorta, E.; Siravegna, G.; Sartore-Bianchi, A.; Scala, E.; Cassingena, A.; Zecchin, D.; Apicella, M.; Migliardi, G.; Galimi, F.; Lauricella, C.; Zanon, C.; Perera, T.; Veronesem, S.; Corti, G.; Amatu, A.; Gambacorta, M.; Diaz, L. A., Jr.; Sausen, M.; Velculescu, V. E.; Comoglio, P.; Trusolino, L.; Di Nicolantonio, F.; Giordano, S.; Siena, S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Cancer Discovery 2013, 3, 658-673
95. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain EMBO J. 1998, 17, 5896-5904 (Pubitemid 28474784)
96. Paulson, A. K.; Linklater, E. S.; Berghuis, B. D.; App, C. A.; Oostendorp, L. D.; Paulson, J. E.; Pettinga, J. E.; Melnik, M. K.; Vande Woude, G. F.; Graveel, C. R. MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance Mol. Cancer Res. 2013, 11, 1112-1121
97. Harbinski, F.; Craig, V. J.; Sanghavi, S.; Jeffery, D.; Liu, L.; Sheppard, K. A.; Wagner, S.; Stamm, C.; Buness, A.; Chatenay-Rivauday, C.; Yao, Y.; He, F.; Lu, C. X.; Guagnano, V.; Metz, T.; Finan, P. M.; Hofmann, F.; Sellers, W. R.; Porter, J. A.; Myer, V. E.; Graus-Porta, D.; Wilson, C. J.; Buckler, A.; Tiedt, R. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth Cancer Discovery 2012, 2, 948-959
98. Timofeevski, S. L.; McTigue, M. A.; Ryan, K.; Cui, J.; Zou, H. Y.; Zhu, J. X.; Chau, F.; Alton, G.; Karlicek, S.; Christensen, J. G.; Murray, B. W. Enzymatic characterization of MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors Biochemistry 2009, 48, 5339-5349
99. Chiara, F.; Michieli, P.; Pugliese, L.; Comoglio, P. M. Mutations in the MET oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity J. Biol. Chem. 2003, 278, 29352-29358 (Pubitemid 36935852)
100. Schiering, N.; Knapp, S.; Marconi, M.; Flocco, M. M.; Cui, J.; Perego, R.; Rusconi, L.; Cristiani, C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor MET and its complex with the microbial alkaloid K-252a Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12654-12659 (Pubitemid 37339954)
101. Wang, W.; Marimuthu, A.; Tsai, J.; Kumar, A.; Krupka, H. I.; Zhang, C.; Powell, B.; Suzuki, Y.; Nguyen, H.; Tabrizizad, M.; Luu, C.; West, B. L. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 3563-3568 (Pubitemid 43376595)
102. Hubbard, S. R.; Wei, L.; Ellis, L.; Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor Nature 1994, 372, 746-754
103. Mroczkowski, B.; McTigue, M. A.; Sarup, J.; Murray, B. W.; Hickey, M.; Parge, H.; Zhu, J. Catalytic Domains of the Human Hepatocyte Growth Factor Receptor Kinase and Material and Methods for Identification Thereof. EP1243596 A1, 2001.
104. Cui, J. J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P. P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363
105. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, S.; Luu, T. L.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3 Z)-ylidenemethyl]-2,4- dimethyl-1 H -pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J. Med. Chem. 2003, 46, 1116-1119 (Pubitemid 36428215)
106. Cui, J.; Zhang, R.; Shen, H.; Chu, J. Y.; Zhang, F.-J.; Koenig, M.; Do, S. H.; Li, X.; Wei, C. C.; Tang, P. C. Preparation of 4-Aryl Substituted Indolinones as Protein Kinase Signal Transduction Modulators for Inhibiting Abnormal Cell Proliferation. PCT Int. Appl. WO0255517, 2002.
107. Cui, J.; Ramphal, Y.; Liang, C.; Sun, L.; Wei, C. C.; Tang, P. C. 5-Aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone Derivatives As Kinase Inhibitors. PCT Int. Appl. WO2002096361 A2, 2002.
108. Wang, X.; Le, P.; Liang, C.; Chan, J.; Kiewlich, D.; Miller, T.; Harris, D.; Sun, L.; Rice, A.; Vasile, S.; Blake, R. A.; Howlett, A. R.; Patel, N.; McMahon, G.; Lipson, K. E. Potent and selective inhibitors of the MET [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion Mol. Cancer Ther. 2003, 2, 1085-1092
109. Christensen, J. G.; Schreck, R.; Burrows, J.; Kuruganti, P.; Chan, E.; Le, P.; Chen, J.; Wang, X.; Ruslim, L.; Blake, R.; Lipson, K. E.; Ramphal, J.; Do, S.; Cui, J. J.; Cherrington, J. M.; Mendel, D. B. A selective small molecule inhibitor of MET kinase inhibits MET-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo Cancer Res. 2003, 63, 7345-7355 (Pubitemid 37413476)
110. Christensen, J. G.; Zou, H. Y.; Arango, M. E.; Li, Q.; Lee, J. H.; McDonnell, S. R.; Yamazaki, S.; Alton, G.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and MET, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther. 2007, 6, 3314-3322
111. Zhang, D.; Zhang, X.; Ai, J.; Zhai, Y.; Liang, Z.; Wang, Y.; Chen, Y.; Li, C.; Zhao, F.; Jiang, H.; Geng, M.; Luo, C.; Liu, H. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors Bioorg. Med. Chem. 2013, 21, 6804-6820
112. Li, J.; Wu, N.; Tian, Y.; Zhang, J.; Wu, S. Aminopyridyl/pyrazinyl spiro[indoline-3,4′-piperidine]-2-ones as highly selective and efficacious MET/ALK inhibitors ACS Med. Chem. Lett. 2013, 4, 806-810
113. Steinig, A. G.; Li, A.-H; Wang, J.; Chen, X.; Dong, H.; Ferraro, C.; Jin, M.; Kadalbajoo, M.; Kleinberg, A.; Stolz, K. M.; Tavares-Greco, P. A.; Wang, T.; Albertella, M. R.; Peng, Y.; Crew, L.; Kahler, J.; Kan, J.; Schulz, R.; Cooke, A.; Bittner, M.; Turton, R. W.; Franklin, M.; Gokhale, P.; Landfair, D.; Mantis, C.; Workman, J.; Wild, R.; Pachter, J.; Epstein, D.; Mulvihill, M. J. Novel 6-aminofuro[3,2- c ]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases Bioorg. Med. Chem. Lett. 2013, 23, 4381-4387
114. Nishii, H.; Chiba, T.; Morikami, K.; Fukami, T. A.; Sakamoto, H.; Ko, K.; Koyano, H. Discovery of 6-benzyloxyquinolines as MET selective kinase inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1405-1409
115. Lovly, C. M.; Heuckmann, J. M.; de Stanchina, E.; Chen, H.; Thomas, R. K.; Liang, C.; Pao, W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors Cancer Res. 2011, 71, 4920-4931
116. Zhang, D.; Ai, J.; Liang, Z.; Zhu, W.; Peng, X.; Chen, X.; Ji, Y.; Jiang, H.; Luo, C.; Geng, M.; Liu, H. Novel 5-(benzyloxy)pyridin-2(1 H)-one derivatives as potent MET inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 2408-2413
117. Hann, M. M.; Keserü, G. M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry Nat. Rev. Drug Discovery 2012, 11, 355-365
118. Tarcsay, A.; Nyíri, K.; Keseru, G. M. Impact of lipophilic efficiency on compound quality J. Med. Chem. 2012, 55, 1252-1260
119. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 2010, 1, 420-434
120. Cui, J. J.; McTigue, M.; Nambu, M.; Tran-Dubé, M.; Pairish, M.; Shen, H.; Jia, L.; Cheng, H.; Hoffman, J.; Le, P.; Jalaie, M.; Goetz, G. H.; Ryan, K.; Grodsky, N.; Deng, Y. L.; Parker, M.; Timofeevski, S.; Murray, B. W.; Yamazaki, S.; Aguirre, S.; Li, Q.; Zou, H.; Christensen, J. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer J. Med. Chem. 2012, 55, 8091-8109
121. Koenig, M.; Cui, J.; Wei, C. C.; Do, S. H.; Zhang, F.-J.; Vojkovsky, T.; Ramphal, J.; Yang, G.; Mattson, M.; Nelson, C.; Tang, P. C. Indolinone Hydrazides as MET Inhibitors. PCT Int. Appl. WO2005005378, 2005.
122. Vojkovsky, T.; Koenig, M.; Zhang, F.-J.; Cui, J. Tetracyclic Compounds as MET Inhibitors. PCT Int. Appl. WO2005004808, 2005.
123. Zhang, F.-J.; Vojkovsky, T.; Huang, P.; Liang, C.; Do, S. H.; Koenig, M.; Cui, J. Preparation of Triazolotriazines as MET Modulators for Treating Cancer. PCT Int. Appl. WO2005010005, 2005.
124. Cui, J.; Botrous, I. Arylmethyl Triazolo and Imidazopyrazines as MET Inhibitors. PCT Int. Appl. WO2005004607, 2005.
125. Cui, J. J.; Shen, H.; Tran-Dubé, M.; Nambu, M.; McTigue, M.; Grodsky, N.; Ryan, K.; Yamazaki, S.; Aguirre, S.; Parker, M.; Li, Q.; Zou, H.; Christensen, J. Lessons from (S)-6-(1-(6-(1-methyl-1 H -pyrazol-4-yl)-[1,2,4]
126. Aguirre, S. A.; Heyen, J. R.; Collette, W., 3rd; Bobrowski, W.; Blasi, E. R. Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor Toxicol. Pathol. 2010, 38, 416-428
127. Hu, W.; Hirakawa, B.; Jessen, B.; Lee, M.; Aguirre, S. A. Tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition J. Appl. Toxicol. 2012, 32, 1008-1020
128. Perera, T.; Lavrijssen, T.; Janssens, B.; Geerts, T.; King, P.; Mevellec, L.; Cummings, M. D.; Lu, T.; Johnson, D.; Page, M. JNJ-38877605: A Selective MET Kinase Inhibitor Inducing Regression of MET-Driven Tumor Models. Presented at the 99th AACR Annual Meeting; San Diego, CA, Apr 12-16, 2008; No. 4837.
129. Buchanan, S. G.; Hendle, J.; Lee, P. S.; Smith, C. R.; Bounaud, P. Y.; Jessen, K. A.; Tang, C. M.; Huser, N. H.; Felce, J. D.; Froning, K. J.; Peterman, M. C.; Aubol, B. E.; Gessert, S. F.; Sauder, J. M.; Schwinn, K. D.; Russell, M.; Rooney, I. A.; Adams, J.; Leon, B. C.; Do, T. H.; Blaney, J. M.; Sprengeler, P. A.; Thompson, D. A.; Smyth, L.; Pelletier, L. A.; Atwell, S.; Holme, K.; Wasserman, S. R.; Emtage, S.; Burley, S. K.; Reich, S. H. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo Mol. Cancer Ther. 2009, 8, 3181-3190
130. Tiedt, R.; Degenkolbe, E.; Furet, P.; Appleton, B. A.; Wagner, S.; Schoepfer, J.; Buck, E.; Ruddy, D. A.; Monahan, J. E.; Jones, M. D.; Blank, J.; Haasen, D.; Drueckes, P.; Wartmann, M.; McCarthy, C.; Sellers, W. R.; Hofmann, F. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients Cancer Res. 2011, 71, 5255-5264
131. Liu, X.; Wang, Q.; Yang, G.; Marando, C.; Koblish, H. K.; Hall, L. M.; Fridman, J. S.; Behshad, E.; Wynn, R.; Li, Y.; Boer, J.; Diamond, S.; He, C.; Xu, M.; Zhuo, J.; Yao, W.; Newton, R. C.; Scherle, P. A. A novel kinase inhibitor, INCB28060, blocks MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3 Clin. Cancer Res. 2011, 17, 7127-7138
132. Albrecht, B. K.; Harmange, J. C.; Bauer, D.; Berry, L.; Bode, C.; Boezio, A. A.; Chen, A.; Choquette, D.; Dussault, I.; Fridrich, C.; Hirai, S.; Hoffman, D.; Larrow, J. F.; Kaplan-Lefko, P.; Lin, J.; Lohman, J.; Long, A. M.; Moriguchi, J.; O'Connor, A.; Potashman, M. H.; Reese, M.; Rex, K.; Siegmund, A.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.; Yang, Y.; Zhang, Y.; Bellon, S. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the MET kinase J. Med. Chem. 2008, 51, 2879-2882 (Pubitemid 351706015)
133. Boezio, A. A.; Berry, L.; Albrecht, B. K.; Bauer, D.; Bellon, S. F.; Bode, C.; Chen, A.; Choquette, D.; Dussault, I.; Fang, M.; Hirai, S.; Kaplan-Lefko, P.; Larrow, J. F.; Lin, M. H.; Lohman, J.; Potashman, M. H.; Qu, Y.; Rex, K.; Santostefano, M.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.; Yang, Y.; Zhang, Y.; Harmange, J. C. Discovery and optimization of potent and selective triazolopyridazine series of MET inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6307-6312
134. Bode, C. M.; Boezio, A. A.; Albrecht, B. K.; Bellon, S. F.; Berry, L.; Broome, M. A.; Choquette, D.; Dussault, I.; Lewis, R. T.; Lin, M. H.; Rex, K.; Whittington, D. A.; Yang, Y.; Harmange, J. C. Discovery and optimization of a potent and selective triazolopyridinone series of MET inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 4089-4093
135. Bladt, F.; Faden, B.; Friese-Hamim, M.; Knuehl, C.; Wilm, C.; Fittschen, C.; Grädler, U.; Meyring, M.; Dorsch, D.; Jaehrling, F.; Pehl, U.; Stieber, F.; Schadt, O.; Blaukat, A. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective MET inhibitors Clin. Cancer Res. 2013, 19, 2941-2951
136. http://clinicaltrials.gov.
137. Dalvie, D.; Sun, H.; Xiang, C.; Hu, Q.; Jiang, Y.; Kang, P. Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide Drug Metab. Dispos. 2012, 40, 1575-1587
138. Infante, J. R.; Rugg, T.; Gordon, M.; Rooney, I.; Rosen, L.; Zeh, K.; Liu, R.; Burris, H. A.; Ramanathan, R. K. Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET Invest. New Drugs 2013, 31, 363-369
139. Diamond, S.; Boer, J.; Maduskuie, T. P., Jr.; Falahatpisheh, N.; Li, Y.; Yeleswaram, S. Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications Drug Metab. Dispos. 2010, 38, 1277-1285
140. Fujiwara, Y.; Miwa, A.; Nakamura, K.; Nishitoba, T.; Osawa, T.; Senga, T. Quinoline Derivative and Quinazoline Derivative Inhibiting Self-Phosphorylation of Hepatocytus Proliferator Receptor, and Medicinal Composition Containing the Same. PCT Int. Appl. WO2003000660, 2003.
141. Elisei, R.; Schlumberger, M. J.; Müller, S. P.; Schöffski, P.; Brose, M. S.; Shah, M. H.; Licitra, L.; Jarzab, B.; Medvedev, V.; Kreissl, M. C.; Niederle, B.; Cohen, E. E.; Wirth, L. J.; Ali, H.; Hessel, C.; Yaron, Y.; Ball, D.; Nelkin, B.; Sherman, S. I. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. [Online early access]. DOI: 10.1200/JCO.2012.48. 4659. Published Online: Sep 3, 2013.
142. Yakes, F. M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A. D.; Engst, S.; Lee, L.; Lesch, J.; Chou, Y. C.; Joly, A. H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol. Cancer Ther. 2011, 10, 2298-2308
143. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K. A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 2009, 69, 8009-8016
144. Nakagawa, T.; Tohyama, O.; Yamaguchi, A.; Matsushima, T.; Takahashi, K.; Funasaka, S.; Shirotori, S.; Asada, M.; Obaishi, H. E7050: a dual MET and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models Cancer Sci. 2010, 101, 210-215
145. Bonfils, C.; Beaulieu, N.; Fournel, M.; Ste-Croix, H.; Besterman, J. M.; Maroun, C. R. The combination of MGCD265, a MET/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis Cancer Res. 2012, 72 (8 Suppl.) 1790
146. Norman, M. H.; Liu, L.; Lee, M.; Xi, N.; Fellows, I.; D'Angelo, N. D.; Dominguez, C.; Rex, K.; Bellon, S. F.; Kim, T. S.; Dussault, I. Structure-based design of novel class II MET inhibitors: 1. Identification of pyrazolone-based derivatives J. Med. Chem. 2012, 55, 1858-1867
147. Liu, L.; Siegmund, A.; Xi, N.; Kaplan-Lefko, P.; Rex, K.; Chen, A.; Lin, J.; Moriguchi, J.; Berry, L.; Huang, L.; Teffera, Y.; Yang, Y.; Zhang, Y.; Bellon, S. F.; Lee, M.; Shimanovich, R.; Bak, A.; Dominguez, C.; Norman, M. H.; Harmange, J. C.; Dussault, I.; Kim, T. S. Discovery of a potent, selective, and orally bioavailable MET inhibitor: 1-(2-hydroxy-2-methylpropyl)- N -(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide (AMG 458) J. Med. Chem. 2008, 51, 3688-3691 (Pubitemid 351956499)
148. Liu, L.; Norman, M. H.; Lee, M.; Xi, N.; Siegmund, A.; Boezio, A. A.; Booker, S.; Choquette, D.; D'Angelo, N. D.; Germain, J.; Yang, K.; Yang, Y.; Zhang, Y.; Bellon, S. F.; Whittington, D. A.; Harmange, J. C.; Dominguez, C.; Kim, T. S.; Dussault, I. Structure-based design of novel class II MET inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series J. Med. Chem. 2012, 55, 1868-1897
149. Schroeder, G. M.; An, Y.; Cai, Z. W.; Chen, X. T.; Clark, C.; Cornelius, L. A.; Dai, J.; Gullo-Brown, J.; Gupta, A.; Henley, B.; Hunt, J. T.; Jeyaseelan, R.; Kamath, A.; Kim, K.; Lippy, J.; Lombardo, L. J.; Manne, V.; Oppenheimer, S.; Sack, J. S.; Schmidt, R. J.; Shen, G.; Stefanski, K.; Tokarski, J. S.; Trainor, G. L.; Wautlet, B. S.; Wei, D.; Williams, D. K.; Zhang, Y.; Zhang, Y.; Fargnoli, J.; Borzilleri, R. M. Discovery of N -(4-(2-amino-3-chloropyridin-4- yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3- carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the MET kinase superfamily J. Med. Chem. 2009, 52, 1251-1254
150. Hurley, L. H.; Mahadevan, D.; Han, H.; Bearss, D. J.; Vankayalapati, H.; Bashyam, S.; Munoz, R. M.; Warner, S. L.; Della Croce, K.; Von Hoff, D. D.; Grand, C. L.; Welsh, J. Preparation of Fused Pyrimidines as Therapeutic Protein Kinase Inhibitors. US2008/0051414, 2008.
151. Baxter, P. A.; Thompson, P. A.; McGuffey, L. M.; Gibson, B. W.; Dauser, R. C.; Nuchtern, J. G.; Shi, C.; Inloes, R.; Choy, G.; Redkar, S.; Blaney, S. M. Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates Cancer Chemother. Pharmacol. 2011, 67, 809-812
152. Pan, B. S.; Chan, G. K.; Chenard, M.; Chi, A.; Davis, L. J.; Deshmukh, S. V.; Gibbs, J. B.; Gil, S.; Hang, G.; Hatch, H.; Jewell, J. P.; Kariv, I.; Katz, J. D.; Kunii, K.; Lu, W.; Lutterbach, B. A.; Paweletz, C. P.; Qu, X.; Reilly, J. F.; Szewczak, A. A.; Zeng, Q.; Kohl, N. E.; Dinsmore, C. J. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated MET receptor Cancer Res. 2010, 70, 1524-1533
153. Munshi, N.; Jeay, S.; Li, Y.; Chen, C. R.; France, D. S.; Ashwell, M. A.; Hill, J.; Moussa, M. M.; Leggett, D. S.; Li, C. J. ARQ 197, a novel and selective inhibitor of the human MET receptor tyrosine kinase with antitumor activity Mol. Cancer Ther. 2010, 9, 1544-1553
154. Katayama, R.; Aoyama, A.; Yamori, T.; Qi, J.; Oh-hara, T.; Song, Y.; Engelman, J. A.; Fujita, N. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to MET inhibition Cancer Res. 2013, 73, 3087-3096
155. Basilico, C.; Pennacchietti, S.; Vigna, E.; Chiriaco, C.; Arena, S.; Bardelli, A.; Valdembri, D.; Serini, G.; Michieli, P. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET Clin. Cancer Res. 2013, 19, 2381-2392
156. Peters, S.; Adjei, A. A. MET: a promising anticancer therapeutic target Nat. Rev. Clin. Oncol. 2012, 9, 314-326
157. Robinson, K. W.; Sandler, A. B. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents Oncologist 2013, 18, 115-122
158. Ma, P. C.; Jagadeeswaran, R.; Jagadeesh, S.; Tretiakova, M. S.; Nallasura, V.; Fox, E. A.; Hansen, M.; Schaefer, E.; Naoki, K.; Lader, A.; Richards, W.; Sugarbaker, D.; Husain, A. N.; Christensen, J. G.; Salgia, R. Functional expression and mutations of MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer Cancer Res. 2005, 65, 1479-1488 (Pubitemid 40270177)
159. Cappuzzo, F.; Marchetti, A.; Skokan, M.; Rossi, E.; Gajapathy, S.; Felicioni, L.; Del Grammastro, M.; Sciarrotta, M. G.; Buttitta, F.; Incarbone, M.; Toschi, L.; Finocchiaro, G.; Destro, A.; Terracciano, L.; Roncalli, M.; Alloisio, M.; Santoro, A.; Varella-Garcia, M. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients J. Clin. Oncol. 2009, 27, 1667-1674
160. Sadiq, A. A.; Salgia, R. MET as a possible target for non-small-cell lung cancer J. Clin. Oncol. 2013, 31, 1089-1096
161. Tanizaki, J.; Okamoto, I.; Okamoto, K.; Takezawa, K.; Kuwata, K.; Yamaguchi, H.; Nakagawa, K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations J. Thorac. Oncol. 2011, 6, 1624-1631
162. Ou, S.-H. I.; Kwak, E. L.; Siwak-Tapp, C.; Dy, J.; Bergethon, K.; Clark, J. W.; Camidge, D. R.; Solomon, B. J.; Maki, R. G.; Bang, Y.-J.; Kim, D.-W.; Christensen, J.; Tan, W.; Wilner, K. D.; Salgia, R.; Iafrate, A. J. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification J. Thorac. Oncol. 2011, 6, 942-946
163. Spigel, D. R.; Ervin, T. J.; Ramlau, R.; Daniel, D. B.; Goldschmidt, J. H.; Blumenschein, G. R.; Krzakowski, M. J.; Robinet, G.; Clement-Duchene, C.; Barlesi, F.; Govindan, R.; Patel, T.; Orlov, S. V.; Wertheim, M. S.; Zha, J.; Pandita, A.; Yu, W.; Yauch, R. L.; Patel, P. H.; Peterson, A. C. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC J. Clin. Oncol. 2011, 29, 7505
164. Ou, S. I.; Govindan, R.; Eaton, K. D.; Otterson, G. A.; Gutierrez, M.; Mita, A. C.; Argiris, A.; Brega, N.; Usari, T.; Tan, W.; Ho, S. N.; Robert, F. Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) J. Clin. Oncol. 2012, 30, 2610
165. Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int. J. Cancer 2010, 127, 2893-2917
166. Goyal, L.; Muzumdar, M. D.; Zhu, A. X. Targeting the HGF/c-MET pathway in hepatocellular carcinoma Clin. Cancer Res. 2013, 19, 2310-2318
167. Park, W. S.; Dong, S. M.; Kim, S. Y.; Na, E. Y.; Shin, M. S.; Pi, J. H.; Kim, B. J; Bae, J. H.; Hong, Y. K.; Lee, K. S.; Lee, S. H.; Yoo, N. J.; Jang, J. J.; Pack, S.; Zhuang, Z.; Schmidt, L.; Zbar, B.; Lee, J. Y. Somatic mutations in the kinase domain of the MET/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas Cancer Res. 1999, 59, 307-310 (Pubitemid 29048858)
168. Sennino, B.; McDonald, D. M. Controlling escape from angiogenesis inhibitors Nat. Rev. Cancer 2012, 12, 699-709
169. Rimassa, L.; Porta, C.; Borbath, I.; Daniele, B.; Salvagni, S.; Van Laethem, J. L.; Van Vlierberghe, H.; Trojan, J.; Kolligs, F.; Weiss, A.; Barahona, N.; Gasbarrini, A.; Lencioni, M.; Pande, A.; Lamar, M.; Chen, Y.; Abbadessa, G.; Schwartz, B.; Santoro, A. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT) J. Clin. Oncol. 2012, 30, 4006
170. Verslype, C.; Cohn, A. L.; Kelley, R. K.; Yang, T.-S.; Su, W.-C.; Ramies, D. A.; Lee, Y.; Shen, X.; Van Cutsem, E. Activity of cabozantinib (XL 184) in hepatocellular carcinoma patients (pts): results from a phase II randomized discontinuation trial (RDT) J. Clin. Oncol. 2012, 30, 4007
171. Schöffski, P.; Garcia, J. A.; Stadler, W. M.; Gil, T.; Jonasch, E.; Tagawa, S. T.; Smitt, M.; Yang, X.; Oliner, K. S.; Anderson, A.; Zhu, M.; Kabbinavar, F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma BJU Int. 2011, 108, 679-686
172. Diamond, J. R.; Salgia, R.; Varella-Garcia, M.; Kanteti, R.; LoRusso, P. M.; Clark, J. W.; Xu, L. G.; Wilner, K.; Eckhardt, S. G.; Ching, K. A.; Lira, M. E.; Schoenmakers, E. F.; Christensen, J. G.; Camidge, D. R. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma J. Clin. Oncol. 2013, 31, e254-258
173. Choueiri, T. K.; Vaishampayan, U.; Rosenberg, J. E.; Logan, T. F.; Harzstark, A. L.; Bukowski, R. M.; Rini, B. I.; Srinivas, S.; Stein, M. N.; Adams, L. M.; Ottesen, L. H.; Laubscher, K. H.; Sherman, L.; McDermott, D. F.; Haas, N. B.; Flaherty, K. T.; Ross, R.; Eisenberg, P.; Meltzer, P. S.; Merino, M. J.; Bottaro, D. P.; Linehan, W. M.; Srinivasan, R. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma J. Clin. Oncol. 2013, 31, 181-186
174. Graziano, F.; Galluccio, N.; Lorenzini, P.; Ruzzo, A.; Canestrari, E.; D'Emidio, S.; Catalano, V.; Sisti, V.; Ligorio, C.; Andreoni, F.; Rulli, E.; Di Oto, E.; Fiorentini, G.; Zingaretti, C.; De Nictolis, M.; Cappuzzo, F.; Magnani, M. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer J. Clin. Oncol. 2011, 29, 4789-4795
175. Catenacci, D. V.; Henderson, L.; Xiao, S. Y.; Patel, P.; Yauch, R. L.; Hegde, P.; Zha, J.; Pandita, A.; Peterson, A.; Salgia, R. Durable complete response of metastatic gastric cancer with anti-MET therapy followed by resistance at recurrence Cancer Discovery 2011, 1, 573-579
176. Lennerz, J. K.; Kwak, E. L.; Ackerman, A.; Michael, M.; Fox, S. B.; Bergethon, K.; Lauwers, G. Y.; Christensen, J. G.; Wilner, K. D.; Haber, D. A.; Salgia, R.; Bang, Y. J.; Clark, J. W.; Solomon, B. J.; Iafrate, A. J. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib J. Clin. Oncol. 2011, 29, 4803-4810
177. Dunn, G. P.; Rinne, M. L.; Wykosky, J.; Genovese, G.; Quayle, S. N.; Dunn, I. F.; Agarwalla, P. K.; Chheda, M. G.; Campos, B.; Wang, A.; Brennan, C.; Ligon, K. L.; Furnari, F.; Cavenee, W. K.; Depinho, R. A.; Chin, L.; Hahn, W. C. Emerging insights into the molecular and cellular basis of glioblastoma Genes Dev. 2012, 26, 756-784
178. Wen, P. Y.; Schiff, D.; Cloughesy, T. F.; Raizer, J. J.; Laterra, J.; Smitt, M.; Wolf, M.; Oliner, K. S.; Anderson, A.; Zhu, M.; Loh, E.; Reardon, D. A. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma Neuro-Oncology 2011, 13, 437-446
179. Chi, A. S.; Batchelor, T. T.; Kwak, E. L.; Clark, J. W.; Wang, D. L.; Wilner, K. D.; Louis, D. N.; Iafrate, A. J. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor J. Clin. Oncol. 2012, 30, e30-33
180. Seiwert, T. Y.; Jagadeeswaran, R.; Faoro, L.; Janamanchi, V.; Nallasura, V.; El Dinali, M.; Yala, S.; Kanteti, R.; Cohen, E. E.; Lingen, M. W.; Martin, L.; Krishnaswamy, S.; Klein-Szanto, A.; Christensen, J. G.; Vokes, E. E.; Salgia, R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma Cancer Res. 2009, 69, 3021-3031
181. Di Renzo, M. F.; Olivero, M.; Martone, T.; Maffe, A.; Maggiora, P.; Stefani, A. D.; Valente, G.; Giordano, S.; Cortesina, G.; Comoglio, P. M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas Oncogene 2000, 19, 1547-1555 (Pubitemid 30175676)
182. Hansen, A. R.; Siu, L. L. Epidermal growth factor receptor targeting in head and neck cancer: Have we been just skimming the surface? J. Clin. Oncol. 2013, 31, 1381-1383
183. Xu, H.; Stabile, L. P.; Gubish, C. T.; Gooding, W. E.; Grandis, J. R.; Siegfried, J. M. Dual blockade of EGFR and MET abrogates redundant signaling and proliferation in head and neck carcinoma cells Clin. Cancer Res. 2011, 17, 4425-4438
184. Seiwert, T.; Sarantopoulos, J.; Kallender, H.; McCallum, S.; Keer, H. N.; Blumenschein, G., Jr. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Invest. New Drugs 2013, 31, 417-424